Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

The neovasculature homing motif NGR: more than meets the eye.

Corti A, Curnis F, Arap W, Pasqualini R.

Blood. 2008 Oct 1;112(7):2628-35. doi: 10.1182/blood-2008-04-150862. Epub 2008 Jun 23. Review.

2.

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.

3.

Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.

Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A.

Cancer Res. 2002 Feb 1;62(3):867-74.

4.

Isoaspartate-dependent molecular switches for integrin-ligand recognition.

Corti A, Curnis F.

J Cell Sci. 2011 Feb 15;124(Pt 4):515-22. doi: 10.1242/jcs.077172. Review.

5.

Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.

Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A.

Mol Immunol. 2006 Apr;43(10):1509-18. Epub 2005 Dec 7.

PMID:
16337683
6.

Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.

Jiang W, Jin G, Ma D, Wang F, Fu T, Chen X, Chen X, Jia K, Marikar FM, Hua Z.

PLoS One. 2012;7(5):e37132. doi: 10.1371/journal.pone.0037132. Epub 2012 May 10.

7.

Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.

Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A.

Cancer Res. 2008 Sep 1;68(17):7073-82. doi: 10.1158/0008-5472.CAN-08-1272.

8.

NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.

Zou M, Zhang L, Xie Y, Xu W.

Anticancer Agents Med Chem. 2012 Mar;12(3):239-46. Review.

PMID:
22263803
9.

Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A.

J Biol Chem. 2002 Dec 6;277(49):47891-7. Epub 2002 Oct 7.

10.

Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.

Dreischalück J, Schwöppe C, Spieker T, Kessler T, Tiemann K, Liersch R, Schliemann C, Kreuter M, Kolkmeyer A, Hintelmann H, Mesters RM, Berdel WE.

Int J Oncol. 2010 Dec;37(6):1389-97.

PMID:
21042706
11.

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.

Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE.

Blood. 2009 May 14;113(20):5019-27. doi: 10.1182/blood-2008-04-150318. Epub 2009 Jan 28.

12.

Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.

Wang RE, Niu Y, Wu H, Hu Y, Cai J.

Anticancer Agents Med Chem. 2012 Jan;12(1):76-86. Review.

PMID:
22023047
13.

Peptides for cell-selective drug delivery.

Svensen N, Walton JG, Bradley M.

Trends Pharmacol Sci. 2012 Apr;33(4):186-92. doi: 10.1016/j.tips.2012.02.002. Epub 2012 Mar 15. Review.

PMID:
22424670
14.

Tumor vasculature targeting through NGR peptide-based drug delivery systems.

Corti A, Curnis F.

Curr Pharm Biotechnol. 2011 Aug;12(8):1128-34. Review.

PMID:
21470145
15.

In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.

Ma W, Li G, Wang J, Yang W, Zhang Y, Conti PS, Chen K.

Amino Acids. 2014 Dec;46(12):2721-32. doi: 10.1007/s00726-014-1828-6. Epub 2014 Sep 3.

PMID:
25182731
16.

Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin.

Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, Bordignon C, Corti A, Rizzardi GP, Musco G.

J Biol Chem. 2008 Jul 11;283(28):19757-68. doi: 10.1074/jbc.M710273200. Epub 2008 May 13.

17.
18.

Solution state conformation and degradation of cyclopeptides containing an NGR motif.

Füzéry AK, Mihala N, Szabó P, Perczel A, Giavazzi R, Süli-Vargha H.

J Pept Sci. 2005 Jan;11(1):53-9.

PMID:
15635727
19.

Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, Moresco RM, Pastorino F, Ponzoni M, Musco G, Curnis F.

Adv Funct Mater. 2017 Sep 26;27(36). pii: 1701245. doi: 10.1002/adfm.201701245.

20.

Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling.

Barbariga M, Curnis F, Spitaleri A, Andolfo A, Zucchelli C, Lazzaro M, Magnani G, Musco G, Corti A, Alessio M.

J Biol Chem. 2014 Feb 7;289(6):3736-48. doi: 10.1074/jbc.M113.520981. Epub 2013 Dec 23.

Supplemental Content

Support Center